Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,074.62 -1,268.80 (-1.97%) CMC Crypto 200
1,304.48 -92.06 (-6.59%)
ANI Pharmaceuticals, Inc. (ANIP)
After hours:
| Previous close | 64.95 |
| Open | 64.95 |
| Bid | 65.16 x 300 |
| Ask | 65.37 x 100 |
| Day's range | 64.68 - 65.60 |
| 52-week range | 37.40 - 70.81 |
| Volume | |
| Avg. volume | 144,136 |
| Market cap | 1.371B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 76.89 |
| EPS (TTM) | 0.85 |
| Earnings date | 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 79.80 |
ZacksSage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
GlobeNewswireANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: DateFriday, May 10, 2024 Time8:30 a.m. ET T
- Zacks
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
